


DynamX Coronary Bioadaptor System, LithiX Hertz Contact Lithotripsy Catheter, and DESyne Coronary Stent System Clinical Studies

DynamX Coronary Bioadaptor System

1. Safety and Efficacy of the DynamX Novolimus-Eluting Coronary Bioadaptor System
 - a. [Verheye S, et al. Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system. EuroIntervention. 2020](#)
 - b. [Verheye S, et al. 24-Month Clinical Follow-Up and Mechanistic Insights From Intravascular Imaging Following Coronary Implantation of the Novel DynamX Bioadaptor Platform. Cardiovasc Revasc Med. 2023](#)
 - c. [Verheye S, et al. Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data. Rev Cardiovasc Med. 2023](#)
2. Safety and Performance of the DynamX Sirolimus-eluting Bioadaptor System:
 - a. [Webster M, et al. Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes. Journal of Interventional Cardiology. 2024](#)
3. BIOADAPTOR RCT
 - a. [Saito S, et al. First randomised controlled trial comparing the sirolimus eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. EClinicalMedicine. 2023](#)
 - b. [Shigeru Saito, MD on behalf of the BIOADAPTOR RCT investigators. BIOADAPTOR RCT – 2-Year Outcomes: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Versus Zotarolimus-Eluting Drug-Eluting Stent. Presented at EuroPCR 2024](#)
4. INFINITY-SWEDEHEART RCT
 - a. [Erlinge D, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden \(INFINITY-SWEDEHEART\): a single-blind, non-inferiority, registry-based, randomised controlled trial. The Lancet. 2024](#)
 - b. [David Erlinge, MD, PhD on behalf of the INFINITY-SWEDEHEART investigators. 1-year and Landmark 6-12 Month Clinical Outcomes from the INFINITY-SWEDEHEART Randomized Clinical Trial: Bioadaptor Implant Compared to a Contemporary Drug-Eluting Stent Among Patients in Complex Lesion Subsets. Presented at TCT 2024](#)
5. DynamX Bioadaptor Hong Kong Registry:
 - a. [Yan B, et al. TCTAP A-078 A Non-randomized, Clinical Registry of the DynamX Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients](#)



[With De Novo Native Coronary Artery Lesions – “DynamX Hong Kong Registry”. JACC. 2022 S49](#)

6. DynamX Bioadaptor in Primary PCI:

- a. [Ho HH, et al. TCTAP A-016 1Year Clinical Outcomes of Patients Treated With DynamX Bioadaptor Drug Eluting Stent in Primary Percutaneous Coronary Intervention. JACC. 2024 S10](#)

7. DYNAMITE Study:

- a. [Leone PP, et al. TCT-345 DYNAMX Bioadaptor Stent Implantation for the Treatment of Complex Coronary Lesions: Insights from the DYNAMITE Study. JACC. 2024 B88](#)

LithiX Hertz Contact Lithotripsy Catheter

1. PINNACLE I Study

- a. [Bennett J. TCT 66794: Mechanistic Effects of Coronary Hertz Contact Intravascular Lithotripsy \(HC-IVL\) on Treatment of Calcified Lesions: PINNACLE I OCT Sub-study Procedural Imaging Outcomes. Presented at TCT 2024 on behalf of the PINNACLE I Investigators](#)

DESyne Coronary Stent System

1. EXCELLA II RCT

- a. [Serruys PW, et al. A randomised comparison of Novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention. 2010](#)
- b. [Iqbal J, et al. DESyne Novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. EuroIntervention. 2016](#)

2. DESyne in Patients with Ischemic Heart Disease – Experience from Jordan:

- a. [Jarrah MI, et al. Applying DESyne coronary stent system in patients with ischemic heart disease: experience from Jordan. Med Devices \(Auckl\). 2018](#)

3. Real-world clinical performance of DESyne NES versus Orsiro SES:

- a. [Chang CC, et al. Real-World Clinical Performance of a Novolimus-Eluting Stent versus a Sirolimus-Eluting Stent. Clin Cardiol. 2024](#)